Figures & data
Figure 1. Patient identification methodology.
Key: dx – diagnosis; ICD-10-CM – International Classification of Diseases Clinical Modification; mets – metastases; PC – prostate cancer.
Figure 2. Patient attrition.
Key: AR – androgen receptor; dx – diagnosis; PC – prostate cancer.
Table 1. Baseline demographics.
Table 2. Charlson Comorbidity Index and select comorbidities.
Figure 3. Number of patients on concomitant medications.
Figure 4. Top 10 therapeutic drug classes prescribed.
Figure 5. pDDIs out of the 100 most commonly prescribed concomitant medications by AR inhibitor.
a Note: B risk ratings require no action and are included in the total interactions listed. Darolutamide had 1 pDDI with a B rating (verapamil HCl); apalutamide and enzalutamide had 2 pDDIs with B ratings each (losartan potassium and losartan/hydrochlorothiazide).
Key: AR – androgen receptor; HCl – hydrochloride; pDDI – potential drug–drug interaction.
Table 3. Implicated enzymes for pDDIs.
Supplemental material